Contribution of Mendelian Disorders to Common Chronic Disease: Opportunities for Recognition, Intervention, and Prevention

American Journal of Medical Genetics - Seminars in Medical Genetics

Volumn 125 C, Issue 1, 2004, Pages 50-65

  Scheuner, Maren T ^a,c   Yoon, Paula W ^b   Khoury, Muin J ^d  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE

Author keywords

Chronic disease; Disease prevention; Family history; Mendelian disorders

Indexed keywords

ARTICLE; AUTOSOMAL DOMINANT DISORDER; BREAST CANCER; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL GENETICS; COLON CANCER; DATA BASE; DIABETES MELLITUS; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; FAMILIAL DISEASE; FAMILY HISTORY; GENETIC RISK; HUMAN; KIDNEY CANCER; MENDELIAN DISORDER; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; THYROID CANCER; UTERUS CANCER;

EID: 0942265684     PISSN: 15524868     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajmg.c.30008     Document Type: Article

References (40)

1. Acheson LS, Wiesner GL, Zyzanski SJ, Goodwin MA, Stange KC. 2000. Family history-taking in community family practice: implications for genetic screening. Genet Med 2:180-185.
2. ACOG Technology Assessment. 2002. Genetics and molecular diagnostic testing. Number 1, July 2002. American College of Obstetrics and Gynecology. Int J Gynaecol Obstet 79: 67-85.
3. American Cancer Society. 2003. Cancer facts & figures 2003. Atlanta, GA: American Cancer Society.
4. American College of Medical Genetics. 1999. Genetic susceptibility to breast and ovarian cancer: assessment, counseling and testing guidelines. ACMG Foundation with support from New York State Department of Health.
5. American College of Medical Genetics/American Society of Human Genetics. 2000. Statement on genetic testing for colon cancer. Joint test and technology transfer committee working group. Genet Med 2:362-365.
6. American College of Obstetricians and Gynecologists. 1997. ACOG committee opinion. Breast-ovarian cancer screening. Number 176, October 1996. Committee on Genetics. Int J Gynaecol Obstet 56:82-83.
7. American Gastroenterological Association. 2001. Medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology 121:198-213.
8. American Heart Association. 2002. Heart and stroke statistics-2003 update. Dallas, TX: American Heart Association.
9. American Society of Human Genetics. 1994. Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet 55:i-iv.
10. American Society of Human Genetics. 1996. Statement on informed consent for genetic research. Am J Hum Genet 59:471-474.
11. American Society of Human Genetics/American College of Medical Genetics. 1998. Test and Technology Transfer Committee Working Group. ASHG/ACMG Statement. Measurement and use of total plasma homocysteine. Am J Hum Genet 63:1541-1543.
12. ASCO Subcommittee on Genetic Testing for Cancer Susceptibility. 1996. Statement of the American Society of Clinical Oncology Genetic testing for cancer susceptibility. J Clin Oncol 14:1730-1736.
13. Bennett RL, Hart KA, O'Rourke E, Barranger JA, Johnson J, MacDermot KD, Pastores GM, Steiner RD, Thadhani R. 2002. Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors. J Genet Counsel 11: 121-146.
14. Brekelmans CTM, Seynaeve C, Bartels CCM, Tilanus-Linthorst MMA, Meijers-Heijboer EJ, Crepin CMG, van Geel AN, Menke M, Verhoog LC, van den Ouweland A, Obdeijn IM, Klijn JGM. 2001. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19:924-930.
15. Diabetes Prevention Program Research Group. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:2486-2497.
17. Fananapazir L. 1999. Advances in molecular genetics and management of hypertrophic cardiomyopathy. JAMA 281:1746-1752.
18. Frezzo TM, Rubenstein WS, Dunham D, Ormond KE. 2003. The genetic family history as a risk assessment tool in internal medicine. Genet Med 5:84-91.
19. Friedman JM, Arbiser J, Epstein JA, Gutmann DH, Huot SJ, Lin AE, McManus B, Korf BR. 2002. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med 4:105-111.
20. Gemmill RM, West JD, Boldog F, Tanaka N, Robinson LJ, Smith DI, Li F, Drabkin HA. 1998. The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. Proc Natl Acad Sci USA 95:9572-9577.
21. Gemmill RM, Bemis LT, Lee JP, Sozen MA, Baron A, Zeng C, Erickson PF, Hooper JE, Drabkin HA. 2002. The TRC8 hereditary kidney cancer gene suppresses growth and functions with VHL in a common pathway. Oncogene 21:3507-3516.
22. Grody WW, Griffin JH, Taylor A, Korf BR, Heit JA. 2001. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 3:139-148.
23. Hayflick SJ, Eiff MP, Carpenter L, Steinberger J. 1998. Primary care physicians' utilization and perceptions of genetics services. Genet Med 1:13-21.
24. Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, De La Chapelle A, Mecklin JP. 2000. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829-834.
25. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Offit K. 2002. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615.
26. King M-C, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B. 2001. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. JAMA 286:2251-2256.
27. King RA, Rotter JI, Motolsky AG, editors. 2002. The genetic basis of common diseases, 2nd edition. New York: Oxford University Press.
28. Koscica KL, Canterino JC, Harrigan JT, Dalaya T, Ananth CV, Vintzileos AM. 2001. Assessing genetic risk: comparison between the referring obstetrician and genetic counselor. Am J Obstet Gynecol 185:1032-1034.
29. McKinnon WC, Baty BJ, Bennett RL, Magee M, Neufeld-Kaiser WA, Peters KF, Sawyer JC, Schneider KA. 1997. Predisposition genetic testing for late-onset disorders in adults. A position paper of the National Society of Genetic Counselors. JAMA 278:1217-1220.
30. Meijers-Heijboer H, van Geel B, van Putten WLJ, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MBE, Bartels CCM, Verhoog LC, van den Ouweland AMW, Niermeijer MF, Brekelmans CTM, Klijn JGM. 2001. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164.
31. Modan B, Hartge P, Hirsch-Yechezkel G, Chetrit A, Lubin F, Beller U, Ben-Baruch G, Fishman A, Menczer J, Struewing JP, Tucker MA, Wacholder S, for the National Israel Ovarian Cancer Study Group. 2001. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345:235-240.
32. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson R, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL. 1999. Breast cancer risk after bilateral prophylactic oophorectomy in BKCA1 carriers. J Natl Cancer Inst 91: 1475-1479.
33. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL. 2002. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622.
34. Scheuner MT, Gordon OK. 2002. Genetic risk assessment for common disease. In: Rimoin DL, Connor JM, Pyeritz RE, editors. Emery and Rimoin's principles and practice of medical genetics, 4th edition. New York: Churchill Livingstone. p 654-674.
35. Scheuner MT, Raffel LJ, Wang S-J, Rotter JI. 1997. The family history: a comprehensive genetic risk assessment method for the chronic conditions of adulthood. Am J Med Genet 71:315-324.
36. Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CID, Sener S, Saslow D, Eyre HJ. 2002. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 52:8-22.
37. Straus SE, Majumdar SR, McAlister FA. 2002. New evidence for stroke prevention. JAMA 288:1388-1395.
38. Sweet KM, Bradley TL, Westman JA. 2002. Identification and referral of families at high risk for cancer susceptibility. J Clin Oncol 20:528-537.
39. Walsh JME, Terdiman JP. 2003. Colorectal cancer screening. JAMA 289:1288-1296.
40. Yoon PW, Scheuner MT, Peterson-Oehlke KL, Gwinn M, Faucett A, Khoury MJ. 2002. Can family history be used as a tool for public health and preventive medicine? Genet Med 4:304-310.